Dupixent® (dupilumab) showed positive topline results in two phase 3 trials
Sanofi announced that two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary endpoints. October 16, 2018